Pneumonia. Bronchopneumonia, unspecified organism
Conditions
Interventions
Intervention 1: Intervention group: Capsules derived from organosulfur (Nicovid capsules are ordered by Surin Salamat Sabz Tehran Company and produced by Esveh Pharmaceutical Company. Each capsule con
Sponsors
Hossein Niktale - the inventor of medicine
Eligibility
Sex/Gender
All
Age
3 Years to 16 Years
Inclusion criteria
Inclusion criteria: Patient age 3 to 16 years The patient does not need a ventilator A patient with pneumonia and hospitalized in the special care, infectious and lung department
Exclusion criteria
Exclusion criteria: History of allergy to allicin-L-cysteine History of allergy to garlic and onion Patients with a history of hypotension or gastrointestinal bleeding Low blood pressure of the patient at the beginning of the study (below 120/80) Immune compromised patients - under chemotherapy, organ and bone marrow transplantation, and patients with autoimmune diseases The patient's inability to swallow oral medication that is not embedded in the NGtube or other delivery method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: The first day of the study before the start of the intervention and the seventh day of the study (the last day of the intervention). Method of measurement: Digital thermometer.;Blood oxygen (SpO2). Timepoint: The first day of the study before the start of the intervention and the seventh day of the study (the last day of the intervention). Method of measurement: Pulse Oximeter.;Erythrocyte Sedimentation Rate (ESR). Timepoint: The first day of the study before the start of the intervention and the seventh day of the study (the last day of the intervention). Method of measurement: Westergren method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Mercury sphygmomanometer.;Heart beat. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Pulse oximeter.;Blood gases. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Blood gas measuring device.;C reactive protein. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Taking blood samples and laboratory kits.;Lactate dehydrogenase. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Electrophoresis method.;D-dimer. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Using Vidas laboratory kit.;Complete blood count(CBC). Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Blood cell counting machine.;Ferritin. Timepoint: At the beginning of the study (before the start of the intervention) and on the seventh day after the start of the intervention. Method of measurement: Use of ELISA laboratory kit(Enzyme-linked immuno_sorbent assay). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholamreza Khademi
Mashhad University of Medical Sciences
Outcome results
None listed